ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1514

Phenotype Differences in HLA-B27 Positive Versus Negative Patients with Ankylosing Spondylitis in a Population That Show Relatively Weaker Association with HLA-B27

Handan Yarkan1, Zhixiu Li2, Gokce Kenar3, Sedat Capar4, Fernur Çapa5, Rudi Steffensen6, Servet Akar7, Dilek Solmaz8, Pınar Cetin9, Berrin Zengin3, Erika de Guzman10, Katie Cremin2, Gerçek Can11, Zeynep Yüce5, Ismail Sari12, Fatos Onen13, Matt Brown2 and Nurullah Akkoc14, 1Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, 2Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, 3Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, 4Statistics, Dokuz Eylul University School of Medicine, Izmir, Turkey, 5Department of Molecular Medicine, Dokuz Eylül University Health Sciences Institute, IZMIR, Turkey, 6Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark, 7Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, 8Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, izmir, Turkey, 9Rheumatology, Dokuz Eylul University Faculty of Medicine, izmir, Turkey, 10Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Austria, 11TURKBIO, İzmir, Turkey, İzmir, Turkey, 12Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, 13TURKBIO, İzmir, Turkey, Izmir, Turkey, 14Rheumatology, Private Practice, Rheumatology, İzmir, Turkey

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: ankylosing spondylitis (AS) and human leukocyte antigens (HLA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

The association of HLA-B*27 and ankylosing spondylitis (AS) is relatively weak in some populations. The aim of this study is to compare the clinical manifestations between HLA-B*27+ and HLA-B*27– patients in a Turkish AS population, which has been reported to have a low HLA-B*27 prevalence.

Methods:

A total of 881 AS patients and 900 healthy controls were included in the analysis. All patients fulfilled the modified New York criteria for AS. Clinical and demographic parameters were compared between the HLA-B*27+ and HLA-B*27– patients. Group comparisons were performed using t-tests for continuous measures that were normally distributed and x2 tests were used for categorical measures.

Results:

HLA-B*27 was positive in 64% of patients (n=561) and 6.3% of controls (n=57). All results are summarized in Table 1. Seventy-four percent of the HLA-B*27+ patients and 60% of HLA-B*27– patients were male (<0.001). HLA-B*27+ patients had a younger age at symptom onset, as well as a shorter delay in diagnosis. Moreover, uveitis and a family history for AS were significantly more frequent among HLA-B*27+ AS patients, whereas co-existent psoriasis and inflammatory bowel disease (IBD) were more frequent among HLA-B*27– patients. Further, HLA-B27+ patients had a 22% higher CRP (P<0.05) and 13% higher ESR (P=0.06) than HLA-B*27– patients. Prevalence of peripheral arthritis, dactylitis, biologic use, hip replacement surgery, family history for psoriasis or IBD or uveitis were not different between the two groups. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Metrology Index (BASMI) were also similar in both groups.

Conclusion:

The results of this study conducted in an AS population with a relatively low prevalence of HLA-B*27 are in line with those of other studies performed in other populations. HLA- B*27+ AS patients are more likely to be males and have an earlier age of symptom onset, and a shorter delay in diagnosis as compared to AS patients lacking HLA-B*27. Moreover, HLA-B*27+ AS patients show a greater risk for occurrence of acute anterior uveitis, a greater familial occurrence, and an elevated CRP/ESR, the latter suggesting that HLA-B*27 carriage influences degree of inflammation in AS.

 

Table 1. Comparison of baseline characteristics between HLA-B*27 positive and negative patients

HLA-B*27+

(n=561)

HLA-B*27–

(n=257)

P value

(n=818)

Male, n (%)

415 (%74)

154 (%59.9)

<0.001

Age, Mean ± SD (year)

43.8 ± 12.2

45.5 ± 12.4

0.07

Age at diagnosis, Mean ± SD (year)

34.1 ± 11.9

38.1 ± 12.5

<0.001

Age of symptom onset, Mean ± SD (year)

27.4 ± 10.1

30.2 ± 11.4

<0.001

Duration of axial symptoms Mean ± SD(year)

16.5 ± 11.1

15.3 ± 11.1

0.18

Delay in diagnosis, Mean ± SD (year)

6.9 ± 8

8.6 ± 9.2

0.009

Family history

 

 

 

Family history of AS, n (%)

207 (36.9%)

50 (19.5%)

<0.001

Family history of psoriasis, n (%)

15 (2.7%)

9 (3.5%)

0.5

Family history of uveitis, n (%)

12 (3.7%)

2 (1.3%)

0.13

Family history of IBD, n (%)

8 (2.5%)

4 (2.5%)

0.99

Peripheral arthritis, n (%)

249 (44.4%)

112 (43.6%)

0.83

Enthesitis, n (%)

222 (39.6%)

110 (42.8%)

0.4

Psoriasis, n (%)

14 (2.5%)

14 (5.4%)

0.03

Uveitis, n (%)

135 (24.1%)

27 (10.5%)

<0.001

IBD, n (%)

14 (2.5%)

24 (9.3%)

<0.001

Dactylitis, n (%)

39 (7%)

27 (10.5%)

0.08

Current biologic use, n (%)

168 (29.9%)

73 (28.4)

0.6

Ever biologic use, n (%)

183 (32.6%)

79 (30.7%)

0.6

Hip prothesis, n (%)

25 (4.5%)

9 (3.5%)

0.52

Elevated CRP, n (%)

353 (62.9%)

135 (52.5%)

0.005

CRP Mean ± SD (mg/l)

21.9 ± 26.2

18 ± 25.6

0.05

ESR, Mean ± SD (mm/h)

33 ± 25.6

29.3 ±23.9

0.06

BASDAI, Mean ± SD

3.7 ± 2.4

3.9 ± 2.3

0.22

BASFI, Mean ± SD

2.9 ± 2.7

3 ± 2.6

0.57

BASMI, Mean ± SD

3.1 ± 2.6

2.9 ±2.3

0.19

 


Disclosure: H. Yarkan, None; Z. Li, None; G. Kenar, None; S. Capar, None; F. Çapa, None; R. Steffensen, None; S. Akar, None; D. Solmaz, None; P. Cetin, None; B. Zengin, None; E. D. Guzman, None; K. Cremin, None; G. Can, None; Z. Yüce, None; I. Sari, None; F. Onen, None; M. Brown, None; N. Akkoc, None.

To cite this abstract in AMA style:

Yarkan H, Li Z, Kenar G, Capar S, Çapa F, Steffensen R, Akar S, Solmaz D, Cetin P, Zengin B, Guzman ED, Cremin K, Can G, Yüce Z, Sari I, Onen F, Brown M, Akkoc N. Phenotype Differences in HLA-B27 Positive Versus Negative Patients with Ankylosing Spondylitis in a Population That Show Relatively Weaker Association with HLA-B27 [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/phenotype-differences-in-hla-b27-positive-versus-negative-patients-with-ankylosing-spondylitis-in-a-population-that-show-relatively-weaker-association-with-hla-b27/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/phenotype-differences-in-hla-b27-positive-versus-negative-patients-with-ankylosing-spondylitis-in-a-population-that-show-relatively-weaker-association-with-hla-b27/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology